Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations

J Clin Endocrinol Metab. 2001 Aug;86(8):3795-800. doi: 10.1210/jcem.86.8.7779.

Abstract

Both cAMP production by adenylyl cyclase and cAMP degradation by phosphodiesterases account for intracellular cAMP levels. We previously demonstrated an increased phosphodiesterase activity in GH-secreting adenomas bearing the gsp oncogene. Here we characterize both the activity and the expression of cAMP-specific phosphodiesterase genes in the human pituitary and in gsp+ and gsp- GH-secreting adenomas and analyze the impact of this intracellular feedback mechanism on the levels of cAMP-responsive element-binding protein phosphorylation. Normal pituitary and gsp- GH-secreting adenomas showed similar phosphodiesterase activities, and 7-fold higher levels were observed in gsp+ tumors. In these tumors the increased activity was mainly owing to isobutyl-methyl-xanthine-sensitive phosphodiesterase 4 and to isobutyl-methyl-xanthine-insensitive isoforms. By semiquantitative RT-PCR, all phosphodiesterase 4 transcripts were expressed in the normal and tumoral pituitary. However, the levels of phosphodiesterase 4C and 4D messenger RNAs were significantly higher in gsp+ than in gsp- GH-secreting adenomas and normal pituitary. Expression of the thyroid-specific isobutyl-methyl-xanthine-insensitive phosphodiesterase 8B was absent in the normal pituitary but detectable in almost all GH-secreting adenomas and higher in gsp+ (P < 0.02). Therefore, this study provides a characterization of phosphodiesterase expression in human pituitary and demonstrates a dramatic induction of the cAMP-specific phosphodiesterases 4C and phosphodiesterases 4D and phosphodiesterases 8B in gsp+ GH-secreting adenomas. Similar levels of cAMP-responsive element-binding protein phosphorylation were observed in gsp- and gsp+ GH-secreting adenomas; however, phosphodiesterase blockade caused an increase in cAMP-responsive element-binding protein phosphorylation that was significantly higher in gsp+ than in gsp- adenomas. Because cAMP-responsive element-binding protein represents the principal end point of the cAMP pathway, these results suggest that the enhanced phosphodiesterase activity may have a significant impact on the phenotypic expression of gsp mutations.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Methyl-3-isobutylxanthine / pharmacology
  • 3',5'-Cyclic-AMP Phosphodiesterases / genetics*
  • 3',5'-Cyclic-AMP Phosphodiesterases / metabolism
  • Adenoma / enzymology
  • Adenoma / genetics*
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • GTP-Binding Protein alpha Subunits, Gs / genetics*
  • Human Growth Hormone / metabolism
  • Humans
  • Isoenzymes / genetics
  • Isoenzymes / metabolism
  • Oncogene Proteins / genetics
  • Phosphorylation
  • Pituitary Gland / enzymology*
  • Pituitary Neoplasms / enzymology
  • Pituitary Neoplasms / genetics*
  • RNA, Messenger / genetics
  • Reference Values
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transcription, Genetic
  • Tumor Cells, Cultured

Substances

  • Cyclic AMP Response Element-Binding Protein
  • Isoenzymes
  • Oncogene Proteins
  • RNA, Messenger
  • Human Growth Hormone
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • GTP-Binding Protein alpha Subunits, Gs
  • 1-Methyl-3-isobutylxanthine